HIV compared with infants unexposed to HIV. Additional studies have also documented an increased risk of low birthweight-due to both intrauterine growth restriction and prematurity-among infants who were exposed to HIV but uninfected compared with infants who were not exposed to HIV. 7, [16] [17] [18] [19] Recent research also has indicated that maternal antiretroviral therapy (ART) during pregnancy may have independent negative effects on infant health and growth [20] [21] [22] ; however, few studies have assessed the effect of HIV and/or ART exposure on long-term health outcomes such as growth. 5 Furthermore, much of the research on health outcomes in children exposed to but uninfected with HIV comes from cohorts in wealthy nations where antiretroviral access and underlying risk factors for poor growth, morbidity, and mortality are different than in the low-resource settings. 5, 23 To better describe the unique health risks of children exposed to HIV in low-resource settings, we evaluated mortality, morbidity, and growth outcomes in children who were infected with HIV and children exposed to but uninfected with HIV in Dar es Salaam, Tanzania, compared with children who were not exposed to HIV from the same periurban community.
Methods
The study sample included 3554 children in Dar es Salaam, Tanzania, who participated in two micronutrient supplementation trials (Clinicaltrials.gov: NCT00197730 and NCT00421668). The first trial randomized infants born to mothers infected with HIV to either daily multivitamins (vitamins B complex, C, and E) or placebo at 6 weeks of age. 24 Children were tested for HIV infection at 6 weeks of age by using the Amplicor HIV-1 DNA assay version 1.5 (Roche Molecular Systems Inc, Pleasanton, California). Tests at 18 months of age were performed using HIV ELISAs followed by Enzygnost anti-HIV-1/2 Plus (Dade Behring, Deerfield, Illinois); discordant results were resolved by using a Western blot test. Samples from children who tested positive at 18 months of age were then backtested via polymerase chain reaction to estimate time of transmission. Infants confirmed to be infected with HIV at baseline (6 weeks of age) serve as the infected with HIV sample for analyses, and infants who were uninfected at baseline serve as the exposed but uninfected with HIV sample. If infants exposed to but uninfected with HIV tested positive for HIV at a later visit, they were censored after their last negative test.
The second trial was implemented with a 2 × 2 factorial design assessing zinc and multivitamins, zinc only, multivitamins only, or placebo among 2400 infants born to women not infected with HIV. 25 To enhance comparability with the first study, we restricted our current analyses to infants who received multivitamins alone or placebo. Multivitamin supplements in both trials were identical in composition and dosage. 24, 25 Infants randomized to multivitamins consumed 1 capsule per day containing 150%-600% of the US Adequate Intake for children aged 0-6 months of age, and 2 capsules per day after 6 months containing 200%-400% of the Adequate Intake for infants 6-12 months of age and 133%-800% of the US Recommended Daily Allowance for children 1-3 years of age. The 2 studies were designed to allow for a pooled analysis; they were conducted in overlapping clinics with similar staff, identical inclusion/exclusion criteria (other than maternal HIV status), and they collected the same demographic and clinical data on all mothers and children. 24, 25 The first trial did not show an effect of multivitamin supplements on morbidity and mortality, 24 or on growth. 26 The second trial, which was not powered to assess the effect of supplements on mortality in a population unexposed to HIV, also did not show substantial effects of multivitamins on morbidity 25 or growth. 27 Approval for both trials was granted by the Harvard T.H. Chan School of Public Health Human Subjects Committee, the Muhimbili University of Health and Allied Science Committee of Research and Publications, the Tanzanian National Institute of Medical Research, and the Tanzanian Food and Drug Authority. All mothers provided written informed consent to enroll themselves and their infants in the studies.
In both trials, mothers were asked to bring children to the clinic for follow-up monthly. During follow-up visits, a trained study nurse performed a standardized assessment of child morbidity based on maternal recall aided by the mother's symptom diary that she received at the previous visit. The symptom diary was a pictorial aid of illness symptoms (eg, diarrhea, vomiting) where mothers were asked to check off which days their child had experienced these symptoms. A trained nurse also measured child anthropometry using standard techniques. 28 Weight was measured on a digital infant balance scale with 10-g precision (Tanita, Arlington Heights, Illinois) and length with 1-mm precision using a rigid length board with an adjustable foot piece. For our analysis, we calculated age-and sexspecific z-scores for 3 anthropometric indexes: weight-forheight (WHZ), height-for-age (HAZ), and weight-for-age (WAZ) using the 2006 World Health Organization (WHO) growth standards. 29 Children who missed their monthly followup appointment were visited at home by a study nurse, and their vital status was confirmed through contact with immediate family members.
Standard of Care
The medical care provided to mothers and children in both trials has been described previously. 24, 25 In brief, mothers and children received medical care in accordance with Tanzanian guidelines. On the basis of earlier findings of the benefits of prenatal multivitamins among women infected with HIV who were not receiving ARTs, 29, 30 all women infected with HIV received supplements containing high doses of vitamins B complex, C, and E during pregnancy and lactation. When the first trial began, ART medication was limited to nevirapine prophylaxis for maternal-to-child transmission. 21 As the trial progressed, access to ARTs expanded rapidly. Beginning in July 2005, women and children were screened for ART eligibility and treated according to national guidelines. For adults, eligibility was based on WHO stage IV disease, or CD4 cell count of ≤200 cells/mL, or WHO stage III and CD4 cell count of ≤350 cells/mL. For children, eligibility was based on CD4% < 20 THE JOURNAL OF PEDIATRICS • www.jpeds.com Volume 180 or pediatric WHO stage III. The standard first-line regimen was stavudine, lamivudine, and nevirapine for adults and zidovudine, lamivudine, and nevirapine for children; alternative drugs were available for specific circumstances. Also in accordance with the WHO and Tanzanian guidelines at the time, mothers infected with HIV were counseled on the risks and benefits of exclusive breastfeeding. Mothers not infected with HIV were encouraged to breastfeed exclusively for 6 months followed by complementary feeding and continued breastfeeding until 2 years. All children received growth monitoring, immunizations, high-dose vitamin A supplementation, and routine medical care for illnesses. Infants born to mothers infected with HIV also received cotrimoxazole prophylaxis until 6 months of age, and continued cotrimoxazole as long as children continued breastfeeding.
Statistical Analyses
Baseline characteristics of the 3 groups were compared using c 2 and ANOVA tests for categorical and continuous variables, respectively. Cox proportional hazards models were used to compare mortality rates with infants who were not exposed to HIV as the reference group. To select covariates for adjusted models, univariate models of common predictors of mortality were conducted and all variables significant at the P < .20 level were retained in adjusted models. A priori, we determined infant sex and treatment group (multivitamin vs placebo) would be retained in all models. Generalized estimating equations with the binomial distribution, log link, and exchangeable covariance structure were used to compare relative risks of common morbidities at each nurse visit across the 3 groups. We determined a priori to also include infant age (<26, 26-52, and ≥52 weeks) in all morbidity models. Covariate selection was similar to that for mortality models, but to enhance consistency and interpretability, we selected the same set of covariates for all multivariate morbidity models-any covariate significant at P < .20 for ≥2 morbidity outcomes was retained in all adjusted morbidity models. Baseline relative risks of stunting, wasting, and underweight were compared using generalized linear models with the logarithm as the link function, empirical variance, and a binomial distribution; time to stunting, wasting, and underweight over follow-up was compared using Cox proportional hazards models. Mixed effects models with restricted cubic splines (with set knots at 10 weeks, 3, 6, 9, and 15 months) were used to model mean HAZ, WAZ, and WHZ in infants from 6 weeks through 18 months of age. Covariates in the mixed effects models were identical to those in models for stunting, wasting, and underweight.
Because the guidelines for the initiation of ARTs changed during the first trial, we were able to assess ART use during pregnancy as an effect modifier of the relationship between the HIV exposure group and mortality. We first created 3 categories for all mothers infected with HIV: mothers who initiated ARTs during pregnancy, mothers with early stage HIV (who would not qualify for ARTs before or after the change of guidelines), and mothers with late-stage HIV who did not receive ARTs during pregnancy. Late-stage HIV was defined based on criteria for ART initiation at the time of the study (WHO stage IV disease, or CD4 ≤ 200 cells/mL, or WHO III and CD4 ≤ 350) during pregnancy or at baseline. Early stage HIV was defined as the inverse of late-stage HIV. For infants whose mothers did not receive ARTs during pregnancy but initiated treatment after birth, we censored the children once the mothers initiated ARTs. To assess effect modification in the Cox proportional hazard models for mortality, we conducted likelihood ratio tests comparing full models containing the infant HIV exposure group as well as interaction terms for the infant HIV exposure group and maternal HIV stage/ ART group versus reduced models that only contained the infant HIV exposure group. When an overall test for effect modification yielded a P < .05, maternal HIV stage/ART use was considered a significant effect modifier, and we repeated our primary analyses stratified by maternal HIV stage/ART group. Because infant feeding mode could be on the causal pathway between the infant HIV exposure group and all health outcomes, we repeated all analyses of adjusted models, excluding infant feeding covariates to assess whether this substantially changed our primary results. All analyses were conducted in SAS version 9.3 (SAS Institute, Cary, North Carolina).
Results
The first trial enrolled 2387 infants of mothers infected with HIV, randomized to multivitamins or placebo at 6 weeks of age. Of these, 264 infants were confirmed to be infected with HIV at baseline and 2088 were confirmed to be uninfected with HIV, and thereby served as the exposed to but uninfected with HIV sample. Randomization occurred between August 2004 and November 2007; follow-up ended in May 2008. The second trial enrolled 2400 infants born to mothers not infected with HIV, approximately one-half of whom were randomized to daily zinc supplementation. The remaining 1202 infants who received only multivitamins or placebo serve as the sample not exposed to HIV. Randomization occurred between September 2007 and December 2009; follow-up ended in July 2010. In longitudinal analyses, there were 264 children infected with HIV at baseline, 187 at age 6 months, 133 at age 12 months, and 104 at age 18 months. There were 2088 children exposed but uninfected with HIV at baseline, 1951 at 6 months, 1734 at 12 months, and 1524 at 18 months and there were 1200 children not exposed to HIV at baseline, 1051 at age 6 months, 869 at 12 months, and 660 at 18 months.
With the exception of infant sex, all baseline variables were significantly different across the 3 HIV exposure groups ( Table I) . On average, mothers not infected with HIV were younger, taller, had larger middle-upper arm circumferences, were less likely to be a housewife without income, were more likely to be married or cohabitating with their partner, and had fewer previous pregnancies. They also lived in households that were more likely to own refrigerators and/or televisions. Infants born to mothers infected with HIV were more likely to be low birth weight, particularly if they were infected with HIV themselves. Infants infected with HIV were also significantly more likely to be born preterm. Breastfeeding practices among mothers infected and not infected with HIV were notably different. Mothers infected with HIV breastfed exclusively for longer than mothers not infected with HIV; however, mothers infected with HIV ceased breastfeeding much earlier than mothers not infected with HIV (mean duration, 4.5 months vs 13.2 months).
Infants born to mothers infected with HIV experienced substantially higher rates of mortality in both crude and adjusted models compared with infants born to mothers not infected with HIV, even when the infants remained uninfected (Table II) . Compared with unexposed infants, infants infected with HIV experienced a nearly 30-fold increase in mortality, and infants exposed to but uninfected with HIV had a nearly 3-fold increase in mortality, even after adjusting for sociodemographic characteristics and infant feeding characteristics.
Infants born to mothers infected with HIV also had higher rates of most common infectious morbidities in crude and adjusted models compared with infants born to *Mortality rate estimated from Poisson regression models. †All hazard ratios, 95% CIs and P values are from Cox proportional hazards models with the exact method for ties. ‡Adjusted model is adjusted for maternal education (0, 1-7 or ≥8 years), occupation (housewife with income, housewife without income, or other), height (cm), number of household assets (0, 1, or 2 from a list that included television and refrigerator), infant sex, and treatment group (multivitamin vs placebo), and time updating covariates for duration of exclusive breastfeeding and duration of any breastfeeding. (Table III) . After adjusting for sociodemographic and infant feeding characteristics, infants infected with HIV had an increased risk of all morbidities assessed ranging from a 46% increase in the risk of diarrhea to an almost 13-fold increase in the risk of hospitalization in multivariate models. Compared with infants who were not exposed to HIV, infants exposed to but uninfected with HIV experienced a significantly increased risk of cough (relative risk [ With regard to growth outcomes, infants infected with HIV experienced significantly impaired growth relative to their peers who were not exposed to HIV at all time periods in both crude and multivariate models (Figure and Table IV; Table IV available at www.jpeds.com). Of particular note, infants infected with HIV already had an increased risk of stunting (RR, 2.59; 95% CI, 1.77-3.78; P < .001), wasting (RR, 2.03; 95% CI, 1.32-3.12; P = .001), and underweight (RR, 5.11; 95% CI, 3.40-7.67; P < .001) by study entry at 6 weeks of age in adjusted models. They also continued to have significantly higher rates of stunting, wasting, and underweight for the duration of follow-up. At 6 weeks of age, infants exposed to but uninfected with HIV had lower mean HAZ, WAZ, and WHZ than infants who were not exposed to HIV; however, only the difference in risk of underweight was significantly different at baseline (adjusted RR, 1.90; 95% CI, 1.33-2.73; P < .001). The mixed effects models with restricted cubic splines show that infants exposed to but uninfected with HIV experienced slower declines in HAZ, WAZ, and WHZ than their unexposed peers; however, the difference was most marked in HAZ, where the curves crossed in the first few months of life. In the Cox proportional hazard models assessing rates of stunting, wasting, and underweight from 6 weeks through 18 months of age, infants exposed to but uninfected with HIV had significantly higher rates of wasting and underweight in the crude models; however, neither remained significant in multivariate models. By contrast, infants who were exposed to but uninfected with HIV had lower rates of stunting over follow-up compared with infants who were not exposed to HIV in both crude and adjusted models (adjusted hazard ratio, 0.64; 95% CI, 0.51-0.81; P < .001). In models that did not include infant feeding as a covariate, estimates of the effect of the infant HIV exposure group on mortality, morbidity, and growth were not substantially different than those from models that adjusted for infant feeding.
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We found that progression of maternal HIV disease and ART use were significant effect modifiers of the relationship between HIV exposure and mortality (Table V; available at www.jpeds.com). Specifically, infants exposed to but uninfected with HIV born to mothers with late-stage HIV who did not receive ARTs during pregnancy had substantially higher rates of mortality than infants of mothers with early stage HIV and infants of mothers who received ARTs during pregnancy. Adjusted hazard ratios for infants who were not infected with HIV who were born to mothers with early stage HIV, mothers with late-stage HIV and no ART during pregnancy, and mothers who received ART during pregnancy compared to infants who were not exposed to HIV were 1.55 (95% CI, 0.63-3.80), 4.96 (95% CI, 1.76-14.04), and 1.92 (95% CI, 0.73-5.05), respectively. The increased rate of mortality in infants of mothers with late-stage HIV who did not receive ARTs during pregnancy was also replicated in models for infants infected with HIV. *n is the sum of the number of nurse visits for all children. †Number of events defined as maternal report of morbidity in the 28 days (4 weeks) before each nurse visit. Denominator for percentage calculations was the total number of nurse visits. ‡Crude relative risk (RR), 95% CI, and corresponding P values were obtained from generalized estimating equations with the binomial distribution, log link, and exchangeable covariance structure. §Adjusted RR, 95% CI, and corresponding P values were obtained from generalized estimating equations with the binomial distribution, log link, and exchangeable covariance structure. Adjusted models were adjusted for child's sex and age (<6, 6-12, and >12 months), treatment group (multivitamin supplement vs placebo) and maternal education (0, 1-7, or 8 years), occupation (housewife with no income, housewife with income, other), marital status (cohabitating with partner, yes vs no), parity (0, 1-4, ≥5), height (tertiles) and age (tertiles) and feeding mode at each nurse visit (exclusive breastfeeding, mixed feeding, or no breastfeeding). ¶P < .10. **P < .05. † †P < .001.
Discussion
In this longitudinal study of >3500 infants born to mothers infected and uninfected with HIV in Dar es Salaam, Tanzania, we found that infants infected with HIV had the highest rates of mortality, morbidity, and all three types of growth failure from 6 weeks through 18 months of age. Infants exposed to but uninfected with HIV also had substantially higher rates of morbidity and mortality than infants who were unexposed to HIV, but mixed outcomes with regard to growth. Infants exposed to but uninfected with HIV were more likely to be underweight at 6 weeks of age; however, they experienced slower declines in HAZ, WAZ, and WHZ over follow-up, and by 18 months of age they actually exhibited a higher mean HAZ score than their counterparts who were not exposed to HIV. Our findings on the increased likelihood of mortality, 4, 6 morbidity, 30 and poor growth 31 among infants infected with HIV are consistent with the literature on pediatric HIV infection in sub-Saharan Africa. Research comparing health outcomes in children exposed to but uninfected with HIV with children unexposed to HIV in low-resource settings is limited; however, our findings corroborate a handful of other studies that found that morbidity 32, 33 and mortality 34, 35 among children exposed to but uninfected with HIV is greater than that of children not exposed to HIV. One explanation for the increased risk of mortality and morbidity in children exposed Figure. Adjusted mean height-for-age, weight-for-age and weight-for-height z-scores in infants who were infected with HIV (HIV+), infants who were exposed to but uninfected with HIV (HIV-EU), and infants who were unexposed to HIV (HIV Unexposed). Curves were creating using mixed effects models with restricted cubic splines with knots at 10 weeks and 3, 6, 9, 12, and 15 months of age. The models are adjusted for maternal height and education, as well as infant sex and treatment group, and household asset score. The adjusted means presented here are for children who received placebo in the parent trial, live in a household with either a television or a refrigerator, whose mother is the median height (156 cm), is a housewife without income, and has 1-7 years of education. Bars represent 95% CIs for each of the 3 groups at 6 weeks and 6, 12, and 18 months of age.
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immune abnormalities in children exposed to but uninfected with HIV compared with unexposed infants, including reduced thymic output (measured with cord blood mononuclear cells to determine T-lymphocyte receptor excision circles), lower naive CD4 counts, 11 as well as reductions in CD4/CD8 ratios and CD41, CD81, and naive T-lymphocyte percentages. 12 In addition, children exposed to but uninfected with HIV are also more likely to be exposed to infections owing to maternal HIV status. 3 In particular, studies from subSaharan Africa have documented higher rates of tuberculosis 13 and Pneumonocystis jirovecii 15 infection in children exposed to but uninfected with HIV compared with their unexposed peers.
Reduced breastfeeding may also be an important cause of increased morbidity and mortality in infants exposed to but uninfected with HIV. In our study, we found that on average, mothers infected with HIV practiced exclusive breastfeeding longer than mothers who were not infected with HIV, but that they also discontinued breastfeeding earlier than mothers who were uninfected with HIV. This is consistent with the counselling that mothers infected with HIV received focusing on the benefits of exclusively breastfeeding over mixed feeding, but also on the continued risk of transmitting the virus to their children with prolonged breastfeeding. Comparing our analyses from models including and excluding infant feeding covariates, we found that adjusting for infant feeding in our analyses explained a small amount of the difference in mortality and growth outcomes, but did not fully explain the effect of the HIV exposure group on morbidity and mortality.
Our finding that infants of mothers with late-stage HIV who did not receive ARTs had the highest rates of mortality supports the handful of other studies that have documented an inverse correlation between maternal HIV disease progression and health outcomes in their children. 36, 37 Interestingly, we also found that infants of mothers who received ARTs had lower rates of mortality than infants of mothers with latestage HIV who did not receive ARTs; however, our power to compare these 2 groups was limited. Although there is strong evidence that maternal ART use during pregnancy and lactation can lower the risk of HIV transmission to her child, 38 our findings add to the growing body of evidence that maternal ARTs may confer health benefits to their children beyond HIV transmission. [39] [40] [41] [42] It is worth noting that, although maternal ART use among mothers with late-stage HIV was associated with lower rates of mortality, infants exposed to but uninfected with HIV still had substantially higher rates of mortality than infants who were not exposed to HIV, regardless of maternal HIV stage and ART use. These findings indicate that, even though the provision of ARTs for mothers during pregnancy and lactation may partially mitigate the effects of HIV exposure on child health, it is unlikely to achieve the same health outcomes for infants exposed to but uninfected with HIV as in infants who are not exposed to HIV.
Our findings on growth outcomes were surprising. Our first finding, that infants exposed to but uninfected with HIV had lower HAZ, WAZ, and WHZ at 6 weeks of age is consistent with the few other studies that have assessed birth size in infants who are unexposed to HIV and infants exposed to but uninfected with HIV in low-resource settings.
5 Surprisingly, however, we found that the infants exposed to but uninfected with HIV in our study experienced slower declines in HAZ, WAZ, and WHZ than their unexposed peers over follow-up, and that ultimately infants exposed to but uninfected with HIV had lower rates of stunting from 6 weeks to 18 months of age, and higher mean HAZ scores by 18 months of age. There are several potential explanations for this counterintuitive result. First, the rate of mortality was higher in infants who were exposed to but uninfected with HIV population, and thus there is likely a survival bias in that the infants who were most likely to become stunted in the exposed but uninfected sample were also at greater risk of death during follow-up. 43 There were also two important systematic differences between our two trial populations that may explain these results. Because a previous trial in urban Dar es Salaam found that multivitamin supplementation (vitamins B complex, C, and E) for mothers infected with HIV during pregnancy and lactation slowed disease progression and delayed maternal mortality, 44 all mothers infected with HIV in our first trial received multivitamin supplementation during pregnancy and lactation, but mothers in our second trial did not. Previous work from our group has shown that the provision of these supplements to women infected with HIV during pregnancy and lactation improves postnatal growth in their offspring. 45 In addition, in accordance with the Tanzanian Ministry of Health and Social Welfare guidelines at the time of the trial, all infants exposed to but uninfected with HIV received prophylactic cotrimoxazole as a strategy to potentially reduce morbidity and mortality. A recent meta-analysis of 10 randomized, controlled trials 46 has indicated that antibiotic use, and particularly cotrimoxazole as a prophylactic for HIV, 47 has the potential to improve linear and ponderal growth in young children.
There are several limitations of our study. Given our study's observational design, and particularly that our data come from two separate trials, we cannot rule out residual confounding. In our analyses, we adjusted for several socioeconomic and demographic characteristics that are strong predictors of child health outcomes; however, we cannot eliminate the possibility that an unmeasured confounder is driving the observed relationships. In particular, although our two trials overlapped in duration, the first trial initiated randomization 3 years before the second trial; thus, secular trends in Dar es Salaam could explain some, but likely not all of our findings-the national mortality rate among children <5 years of age in Tanzania decreased by only 7.1% from 2000 to 2012. 48 In addition, the majority of our participants enrolled and completed study followup in the pre-ART era, so we have limited capacity to extrapolate our findings to populations where there is greater access to ARTs. Owing to the change in national guidelines on ART use during our study, we were able to conduct subanalyses accounting for maternal HIV progression and ART use; however, we had limited power for these analyses. It is worth noting that, even after stratifying by maternal disease progression and ART use, our findings on poorer health outcomes for infants exposed to but uninfected with HIV and infants infected with HIV did not change substantially.
Our study also has several strengths. To our knowledge, this is one of the largest studies in a low-resource setting to longitudinally and monthly assess mortality, morbidity, and growth in children who are infected with HIV, children exposed to but uninfected with HIV, and children who are unexposed to HIV. The prospective, longitudinal study design and the collection of comprehensive data on sociodemographic characteristics, infant feeding practices, and maternal HIV disease progression and ART use allowed us to conduct rigorous analyses accounting for important confounders and effect modifiers. In addition, the frequent follow-up visits enabled us to include monthly morbidity and growth outcomes.
Our findings demonstrate that infants born to mothers infected with HIV have substantially poorer health outcomes than infants born to mothers who are not infected with HIV, regardless of infant HIV infection status. Although infants infected with HIV had dramatically inferior health and growth outcomes, infants exposed to but uninfected with HIV in our study also experienced a nearly 3-fold risk of mortality and higher rates of numerous morbidities compared with their unexposed peers. These poor health outcomes remained even after accounting for sociodemographic characteristics, infant feeding practices, and maternal disease progression and ART use. Interestingly, infants exposed to but uninfected with HIV had improved growth outcomes during the 18 months of followup. Our findings highlight the importance of targeting not only infants infected with HIV, but also infants exposed to but uninfected with HIV, in child health and HIV care and treatment programs in low-resource settings, if continued progress in improving child health is to be made. ■ Table IV . Comparing rates of stunting, wasting and underweight in infants who were unexposed to HIV, exposed to but uninfected with HIV, and infected with HIV ‡One-year mortality rate estimated from Poisson regression models. §All hazard ratios, 95% CIs, and P values are from Cox proportional hazards models with the exact method for ties. ¶Adjusted models were adjusted for maternal education (0, 1-7, or ≥8 years), occupation (housewife with income, housewife without income, or other), height (cm), number of household assets (0, 1, or 2 from a list that included television and refrigerator), and infant sex and treatment group (multivitamin vs placebo), as well as time-varying covariates for breastfeeding duration and exclusive breastfeeding duration.
